NCT04748757

Annexin A5 in Patients With Severe COVID-19 Disease

Annexin A5 in Patients With Severe COVID-19 Disease: A Single Centre, Randomized, Double-blind, Placebo-controlled Pilot Trial

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Randomized, double-blind, placebo-controlled trial comparing 2 doses of SY-005 (recombinant human Annexin A5) to placebo in patients with severe coronavirus 2019 disease in a single hospital centre with 2 intensive care units

Conditions

• Coronavirus Infection
• Sepsis

Interventions

Type	Name	Description
DRUG	recombinant human annexin A5	recombinant human annexin A5, manufactured as SY-005
DRUG	Placebo	Normal saline 50 ml

Timeline

• Start date: 2021-04-20
• Primary completion: 2022-04-03
• Completion: 2022-12-01
• First posted: 2021-02-10
• Last updated: 2023-03-08

Locations

1 site across 1 country: Canada